Condiciones de salud que N-acetil-cisteÃna (NAC) puede ayudar a apoyar.
NAC has been evaluated in clinical and dermatological studies for acne vulgaris, primarily due to its antioxidant and anti-inflammatory properties that may reduce oxidative stress in sebaceous follicles. A review in the Journal of Clinical and Aesthetic Dermatology found efficacy signals for NAC in acne vulgaris, both topically and orally. Evidence is preliminary and larger controlled trials are needed.
NAC is a cysteine prodrug and glutathione precursor with well-documented evidence for reducing drug craving across multiple substance use disorders. A 2024 meta-analysis of 11 RCTs (n≈623) found NAC significantly reduced craving ratings (SMD −0.61) versus placebo across alcohol, cocaine, nicotine, amphetamine, and cannabis use disorders. Its mechanism involves rebalancing glutamate homeostasis in the nucleus accumbens and prefrontal cortex.
NAC is a glutathione precursor and direct antioxidant studied in ALS because ALS patients have elevated oxidized glutathione levels and reduced antioxidant capacity. Weekly NAC infusions in ALS patients reduced inflammatory cytokine levels in peripheral blood. Preclinical data show NAC increases glutathione levels and protects motor neurons from degeneration in ALS models.
NAC is a well-established antioxidant agent with robust clinical and mechanistic evidence. Its primary mechanism is serving as a cysteine precursor that replenishes intracellular glutathione (GSH), the body's principal endogenous antioxidant. Additional mechanisms include direct scavenging of reactive oxygen species and reduction of disulfide bonds. Clinical trials across multiple conditions confirm that NAC supplementation measurably elevates GSH levels and total antioxidant capacity.
NAC has preliminary clinical evidence for anxiety disorders, primarily through its modulation of glutamate neurotransmission and reduction of oxidative neuroinflammation. A systematic review of NAC in psychiatry and neurology classified anxiety among disorders with preliminary evidence requiring larger confirmatory studies. A 2025 narrative review similarly noted limited but suggestive anxiolytic effects in clinical populations.
NAC is a glutathione precursor and mucolytic agent with well-documented use in respiratory conditions. It reduces mucus viscosity, scavenges reactive oxygen species, and has anti-inflammatory properties via NF-κB inhibition. NAC has been studied as an adjunct in asthma, particularly for its mucolytic and antioxidant benefits, and is listed among principal natural treatments for asthma in evidence-based reviews.
NAC is a glutathione precursor with antioxidant and immunomodulatory properties that has been clinically studied in SLE, RA, and multiple sclerosis. In a randomized pilot trial in SLE, NAC supplementation reduced disease activity (SLEDAI) and fatigue scores. It corrects glutathione deficiency common in autoimmune diseases and modulates mTOR signaling in T cells.
NAC has demonstrated blood pressure-lowering effects in clinical studies, primarily linked to its homocysteine-lowering and antioxidant properties. A reanalysis of two double-blind, placebo-controlled RCTs in 82 unmedicated middle-aged men found that 1.8 g/day NAC for 4 weeks significantly reduced systolic blood pressure in both normolipidemic and hyperlipidemic subjects.
Clinical evidence indicates NAC can reduce fasting plasma glucose and insulin resistance markers in metabolic populations. An RCT in 76 patients with metabolic syndrome found 1800 mg/day NAC for 12 weeks significantly reduced fasting glucose, fasting insulin, and insulin resistance index. Animal data strongly support antidiabetic effects, though human trial results are mixed and context-dependent.
N-Acetyl Cysteine is a precursor to glutathione, the brain's primary antioxidant, and modulates glutamate neurotransmission. It has been studied for brain fog in post-COVID syndrome and neuropsychiatric conditions. A 2021 PMC review found NAC effective for treating neuropsychiatric symptoms including cognitive dysfunction in post-COVID/PCS, and preclinical and clinical data support its anti-neuroinflammatory and neuroprotective effects.
NAC is one of the most rigorously studied mucolytic agents for bronchial conditions. Multiple meta-analyses of randomized controlled trials demonstrate that oral NAC significantly reduces exacerbation frequency in chronic bronchitis and COPD. A 2019 meta-analysis of 11 RCTs (n=1,564) found NAC reduced chronic bronchitis exacerbations with RR=0.81 (95% CI 0.69–0.93, p=0.004). It acts as a mucolytic by cleaving disulfide bonds in mucin and as an antioxidant via glutathione replenishment.
NAC has extensive RCT evidence for both acute and chronic bronchitis. A meta-analysis of 11 RCTs (775 patients) found NAC significantly reduced chronic bronchitis exacerbation frequency (RR=0.81). A second meta-analysis of 13 studies (4,155 patients) confirmed fewer exacerbations (RR=0.75, p<0.01). A double-blind RCT found 200 mg NAC thrice daily significantly reduced cough, sputum volume, and viscosity in acute bronchitis.
N-Acetyl Cysteine (NAC) has documented fungistatic activity against Candida albicans biofilms in vitro, reducing biofilm viability and thickness by disrupting the biofilm matrix through its sulfhydryl group. Multiple in vitro studies confirm its ability to inhibit both biofilm formation and mature biofilm integrity in drug-susceptible and fluconazole-resistant strains. It is used in Candida cleanse protocols as a biofilm disruptor and liver support agent.
N-acetyl cysteine (NAC) is a glutathione precursor with antioxidant properties and has been included in validated clinical supplement formulas for CTS perioperative support alongside ALA, ALCAR, methylcobalamin, curcumin, and serrapeptidase. It reduces oxidative stress implicated in nerve ischemia and compression.
NAC has documented anti-inflammatory effects in multiple clinical trials, primarily through antioxidant mechanisms and NF-κB inhibition. Meta-analyses of RCTs report significant reductions in pro-inflammatory cytokines IL-6, IL-8, and TNF-α, and in the oxidative stress marker MDA, though effects on CRP are inconsistent across studies.
N-Acetyl Cysteine (NAC) has documented clinical and preclinical evidence supporting a role in mitigating age-related and dementia-associated cognitive decline, primarily through its function as a glutathione precursor that counters oxidative stress and neuroinflammation. Human trials testing NAC alone have yielded modest and inconsistent results, while combination nutraceutical formulations containing NAC have shown more consistent pro-cognitive benefits in Alzheimer's disease patients and older adults with mild cognitive impairment. The overall human evidence base remains preliminary, with no large-scale RCTs yet confirming NAC monotherapy for cognitive aging.
NAC has clinical evidence for reducing influenza-like illness severity. A landmark Italian double-blind RCT found elderly individuals taking NAC 600 mg twice daily during flu season had significantly fewer symptomatic flu episodes and milder symptoms vs. placebo. NAC acts as a mucolytic and glutathione precursor supporting antioxidant defense during respiratory infections. AAFP and ConsumerLab list NAC among effective cold and flu remedies.
N-acetyl cysteine (NAC) has been investigated in experimental colitis models and mentioned in reviews as potentially controlling and preventing ulcerative colitis. It serves as a glutathione precursor, reducing oxidative stress in inflamed colonic mucosa. A study demonstrated molecular evidence for its benefits in experimental colitis.
NAC is a precursor to glutathione, the brain's primary antioxidant, and directly counters the oxidative stress surge post-concussion. A military clinical trial of NAC in blast-induced mTBI showed significant symptom reduction. Preclinical studies in two rodent models found NAC administered 30–60 minutes post-injury significantly reversed behavioral deficits associated with TBI. A 2024 Frontiers in Neurology longitudinal clinical study (n=50 chronic mTBI patients) found NAC treatment improved functional MRI connectivity and cognitive performance versus controls.
NAC is a mucolytic and antioxidant agent extensively studied in COPD. It acts as a glutathione precursor, reducing oxidative stress and mucus viscosity. Multiple meta-analyses and RCTs show high-dose NAC (600 mg twice daily) reduces exacerbation frequency and improves small airway function in stable COPD patients. Evidence is mixed at low doses.
NAC has been examined in inflammatory bowel disease including Crohn's disease as an adjunctive antioxidant and anti-inflammatory agent. A 2024 PMC review identified Crohn's disease among conditions for which NAC may be beneficial. Clinical evidence is limited but involves measurable anti-inflammatory effects in IBD populations.
N-Acetyl Cysteine (NAC) has been studied as an adjunct for depression, particularly in bipolar depression. It is a glutathione precursor that normalizes glutamate transmission and oxidative stress. Multiple RCTs and meta-analyses have found NAC supplementation reduces depressive symptoms as an adjunct to standard treatments.
N-acetylcysteine has demonstrated significant antiproliferative and antioxidant effects on endometriotic tissue. A prospective study found 600 mg three times daily for three consecutive days per week over three months reduced ovarian endometrioma cyst size. A combination RCT (LEAP study) with NAC, alpha-lipoic acid, and bromelain showed reduced endometriosis-related pelvic pain.
N-acetyl cysteine (NAC) is a cysteine precursor that replenishes glutathione, the master antioxidant and primary hepatic chelator for heavy metals and environmental toxins. It has demonstrated chelating activity for mercury, lead, arsenic, and cadmium in both animal and human studies, and is used clinically as an adjunctive agent in heavy metal toxicity management.
NAC has clinical evidence primarily in myoclonic epilepsy of the Unverricht-Lundborg type (progressive myoclonic epilepsy), where it has been used as an adjunctive treatment. A systematic review of NAC in psychiatry and neurology identified progressive myoclonic epilepsy as a condition with favorable clinical evidence. Broader anticonvulsant effects in other epilepsy types are primarily preclinical.
N-acetyl cysteine (NAC) is a precursor to glutathione and a direct antioxidant that protects sperm from oxidative stress-induced damage. A meta-analysis of 3 RCTs (n=431 infertile men) found NAC supplementation significantly improved sperm numbers, motility, and morphology. When combined with selenium in a 4-arm RCT, it significantly improved all semen parameters with dose-dependent correlations.
NAC, a precursor to glutathione, has shown clinical benefit for fertility in women with PCOS. A 2015 meta-analysis of 8 RCTs (n=910) found women receiving NAC had three times higher odds of pregnancy and live birth compared to placebo. Evidence is primarily in PCOS-related infertility at doses of 1200–1800 mg/day.
N-acetylcysteine (NAC) disrupts H. pylori biofilms and has mucolytic activity that increases antibiotic penetration of the gastric mucus layer, improving H. pylori eradication. It was included in a clinical trial evaluating non-antibiotic therapy for H. pylori-associated gastritis, where significant symptom improvement and reduction of gastric inflammation markers were observed.
NAC has preliminary evidence in glaucoma based on its ability to reduce oxidative stress in retinal ganglion cells and suppress autophagy induced by ocular hypertension. Current human evidence is early-stage, with animal studies showing that NAC reduces retinal damage caused by elevated intraocular pressure. A 2024 clinical review identified glaucoma as a condition warranting further NAC investigation.
N-acetyl cysteine serves as a direct precursor to glutathione, the body's primary endogenous antioxidant, which declines markedly with age. Multiple clinical studies document NAC's ability to restore glutathione levels, reduce oxidative stress, support immune function, and mitigate age-related mitochondrial dysfunction. ConsumerLab identifies it as a key agent for antioxidant support.
N-acetyl cysteine (NAC) is a precursor to glutathione, the main cellular antioxidant in cochlear hair cells. Multiple animal studies demonstrate NAC significantly reduces noise-induced cochlear hair cell loss and permanent threshold shifts. A ScienceDirect 2006 study showed NAC significantly reduced permanent threshold shifts and hair cell loss in animals when given 1–4 hours post-noise exposure. Human results are mixed but mechanistically well supported.
NAC has multiple documented cardiovascular effects in human studies, including lowering plasma homocysteine, modest blood pressure reduction, anti-platelet activity, and protection against contrast-induced nephropathy in cardiac patients. Two double-blind RCTs found that 1.8 g/day NAC for 4 weeks significantly reduced plasma homocysteine and systolic blood pressure. Perioperative IV NAC has also been studied in cardiac surgery populations.
N-acetyl cysteine (NAC) is a well-documented precursor to glutathione and a direct thiol-based chelator of heavy metals including mercury, lead, cadmium, and arsenic. A systematic review found NAC chelated toxic metals in 33 animal studies and 15 human studies with no significant adverse effects. It is used as both a chelation adjunct and antioxidant support in heavy metal detox protocols.
NAC may lower plasma homocysteine by displacing it from protein-bound forms and by serving as a cysteine precursor that supports the transsulfuration pathway toward glutathione synthesis. A small clinical study found that 4000 mg/day effervescent NAC for 2 weeks lowered homocysteine levels by 45% vs. placebo. The Linus Pauling Institute and other authorities identify NAC as a supportive agent in homocysteine metabolism.
N-Acetyl Cysteine (NAC) is the rate-limiting precursor to glutathione, the master antioxidant and Phase II conjugation molecule critical for neutralizing reactive estrogen quinones formed during estrogen metabolism. Research shows NAC reduces adduct formation from 4-OH estrogen metabolites and supports the glutathione conjugation arm of Phase II detoxification. It is explicitly listed as a required supportive nutrient for Phase II hormone detox.
N-acetyl cysteine is a precursor to glutathione, the principal endogenous antioxidant, and has been studied in IBD for its ability to reduce oxidative stress and mucosal inflammation. Clinical and preclinical evidence supports its role in reducing NF-κB activation and oxidative damage in colonic tissue relevant to IBD.
NAC has demonstrated improvements in insulin sensitivity in clinical trials in metabolic syndrome and PCOS populations. An RCT in 76 patients with metabolic syndrome found 1800 mg/day NAC for 12 weeks significantly reduced the insulin resistance index (HOMA-IR, p=0.005). NAC also improves insulin sensitivity in PCOS as part of its documented metabolic effects in that population.
N-Acetyl Cysteine (NAC) is a well-established nephroprotective agent, most notably for preventing contrast-induced nephropathy (CIN) in patients undergoing radiographic procedures. Multiple meta-analyses and clinical trials support its use to protect kidney function by replenishing glutathione, a key renal antioxidant. It is also studied for protection against cisplatin nephrotoxicity and as a supportive treatment in CKD.
NAC is the precursor to hepatic glutathione, the liver's primary endogenous antioxidant and detoxification agent. It is FDA-approved (IV form) as the standard-of-care antidote for acetaminophen overdose-induced liver failure. Research also demonstrates benefits in drug-induced liver injury and NAFLD, with clinical trials showing reductions in ALT and improvements in serum albumin and bilirubin.
NAC is one of the most extensively documented respiratory therapeutics, with clinical evidence for COPD, cystic fibrosis, chronic bronchitis, and idiopathic pulmonary fibrosis. It acts as a mucolytic, antioxidant, and anti-inflammatory agent, replenishing intracellular glutathione in the lung. High-dose NAC (600 mg twice daily) significantly reduced exacerbation frequency in stable COPD in RCT evidence.
N-Acetyl Cysteine (NAC) is a glutathione precursor with demonstrated protective effects on RPE cells in AMD. A 2019 PMC study using primary human RPE cultures from AMD donors showed NAC pretreatment reduced ROS production, protected against H2O2-induced cell death, improved mitochondrial function, and increased glutathione content specifically in AMD RPE cells. NAC is included in registered AMD supplement clinical trials (NCT03946085 at 500 mg/day).
NAC has been investigated for memory and cognitive function in clinical trials, particularly in neurodegeneration and schizophrenia. A controlled trial in multiple sclerosis patients found NAC significantly improved cerebral glucose metabolism in brain regions linked to memory and cognition. A meta-analysis found NAC improved working memory as a domain of schizophrenia symptoms after ≥24 weeks of treatment.
N-Acetyl Cysteine (NAC) has direct human clinical evidence supporting its use in metabolic syndrome. As a glutathione precursor with antioxidant and anti-inflammatory properties, NAC targets the oxidative stress and chronic inflammation that underpin metabolic syndrome. A randomized, double-blind, placebo-controlled trial in MetS patients found that 1800 mg/day of NAC for 12 weeks significantly improved fasting glucose, insulin resistance, HDL-cholesterol, and CRP. Evidence base is promising but still limited in scale, and larger trials are needed.
N-Acetyl Cysteine (NAC) supports metabolic health primarily as a glutathione precursor that reduces oxidative stress, a key driver of insulin resistance and metabolic dysfunction. Clinical trials in metabolic syndrome patients show NAC (1800 mg/day for 12 weeks) significantly reduced fasting glucose, fasting insulin, and insulin resistance indices while raising HDL-cholesterol. Evidence also exists for benefit in NAFLD-related metabolic complications, though larger trials are still needed to confirm many findings.
NAC is the most studied precursor to glutathione (GSH), the primary mitochondrial antioxidant. By replenishing intracellular and mitochondrial GSH pools, NAC protects the ETC from oxidative damage and has been shown to improve mitochondrial function in models of GSH depletion, aging, and mitochondrial disease.
NAC is the primary precursor to glutathione, the key antioxidant depleted by mycotoxin exposure. Multiple in vitro studies show NAC pretreatment reduces mycotoxin-induced ROS, apoptosis, and mitochondrial dysfunction in intestinal and hepatic cell lines exposed to zearalenone and patulin. A 2014 PubMed review specifically documented glutathione deficiency as central to mycotoxin-related illness, establishing NAC's rationale. Authoritative integrative medicine sources include NAC as a core mycotoxin detox support agent at 600–1800 mg/day.
NAC is a well-established mucolytic that hydrolyzes disulfide bonds in mucin, reducing mucus viscosity and facilitating airway clearance. A 2024 systematic review confirmed significant inhibitory effects on MUC5AC and MUC5B gene and protein expression, and reduction of goblet cell hyperplasia. A large multicenter RCT (n=333) demonstrated IV NAC superior to placebo for improving sputum viscosity and expectoration difficulty in hospitalized patients with respiratory disease.
N-Acetyl Cysteine is a precursor to glutathione, the brain's primary antioxidant, and modulates glutamatergic neurotransmission. Multiple clinical trials and meta-analyses support its use for psychiatric and neurological conditions including OCD, depression, bipolar disorder, and neuroprotection.
N-Acetyl Cysteine is a precursor to glutathione, the body's primary endogenous antioxidant, and has demonstrated relevance to peripheral neuropathy through reduction of oxidative stress in nerve tissue. A 2022 MDPI peer-reviewed review identifies it as an amino acid-derived supplement with evidence for neuropathic pain treatment alongside acetyl-L-carnitine. It is included in authoritative neuropathy supplement evidence databases and used in chemotherapy-induced neuropathy management.
NAC directly modulates glutamate homeostasis in the brain via the cystine-glutamate antiporter and indirectly modulates dopamine signaling. These mechanisms underpin its clinical investigation across multiple psychiatric and neurological conditions including schizophrenia, bipolar disorder, OCD, and addiction. Multiple clinical trials document neurochemical changes with NAC treatment.
NAC has been studied as an antioxidant therapy in both acute and post-ERCP pancreatitis due to its glutathione-precursor and anti-inflammatory properties. Animal studies show it improves pancreatic microvascular perfusion and reduces necrosis in acute necrotizing pancreatitis. A 2007 randomized double-blind placebo-controlled trial (n=43) of IV antioxidants including NAC in severe AP found no significant benefit on organ dysfunction, showing mixed clinical results.
N-Acetyl Cysteine (NAC) raises brain glutathione levels and has been studied in Parkinson's disease as a neuroprotective antioxidant. A pilot clinical trial (Thomas Jefferson University, 2019) showed NAC increased dopamine transporter binding on DaTSCAN and significantly improved UPDRS scores in PD patients. Larger trials are needed.
NAC is an acetylated derivative of L-cysteine with potent antioxidant properties. Multiple RCTs and meta-analyses show NAC improves ovulation rates, pregnancy rates, and reduces testosterone and insulin resistance in women with PCOS. One meta-analysis of 18 studies (2,185 women) found significant testosterone reduction and improved reproductive function.
NAC has RCT evidence for improving oxidative stress and inflammatory markers in community-acquired pneumonia and for preventing ventilator-associated pneumonia (VAP). A randomized double-blind placebo-controlled trial demonstrated NAC 600 mg twice daily significantly reduced VAP incidence in ICU patients. A 2018 RCT found NAC reduced plasma MDA and TNF-α in CAP patients versus conventional treatment alone.
A precursor to glutathione, NAC replenishes the principal antioxidant depleted during illness-induced oxidative stress. It has been studied in post-illness and post-injury recovery settings with documented anti-inflammatory and mucolytic effects. Included in peer-reviewed protocols for recovery from traumatic brain injury and respiratory illness.
N-Acetyl Cysteine (NAC) is a mucolytic agent that directly breaks disulfide bonds in mucus glycoproteins, reducing viscosity and improving mucociliary clearance. A randomized, double-blind, placebo-controlled study confirmed NAC significantly improved nasal mucociliary clearance time (p=0.021) versus placebo. NAC also reduces biofilm formation and inhibits pro-inflammatory cytokines, making it relevant to infection-related and chronic post-nasal drip.
N-Acetyl Cysteine (NAC) is a precursor to glutathione and reduces post-surgical oxidative stress and inflammation. It is among three amino acids (arginine, glutamine, cysteine) classified as conditionally indispensable under surgical trauma. Clinical supplementation studies support its use for perioperative antioxidant protection.
NAC replenishes glutathione stores depleted during viral infection and post-viral inflammatory states, and is recommended in published long COVID treatment protocols. The VA Long COVID clinical guide (2023) and integrative medicine reviews (Liebertpub, 2025) include NAC for mitochondrial support and oxidative stress reduction. NAC has RCT evidence in viral respiratory illness contexts for reducing cytokine levels and symptom severity.
N-Acetyl Cysteine (NAC) is used in SIBO treatment as a biofilm disruptor. NAC breaks disulfide bonds in bacterial biofilm matrices, exposing embedded bacteria to concurrent antimicrobials. Published clinical evidence (Cureus, PMC12701763) includes its use in herbal SIBO antimicrobial protocols, and Del Piano et al. found a regimen combining Lactobacillus strains with NAC significantly reduced small bowel bacterial overgrowth.
NAC is a well-established mucolytic agent used clinically to reduce mucus viscosity in respiratory and sinus conditions. Its mucolytic action on airway and nasal secretions is the basis of decades of clinical use in COPD and cystic fibrosis, and it has been applied to chronic rhinosinusitis. A 2026 expert consensus document (NECTAR) affirmed NAC's role in reducing mucus burden across respiratory phenotypes.
NAC functions as a mucolytic agent in sinusitis by breaking disulfide bonds in mucopolysaccharide fibers, reducing mucus viscosity, and disrupting bacterial biofilms. A 2024 narrative review in Sage Journals identified NAC among supplements with 'growing positive evidence' for sinusitis. A clinical trial (NCT04123405) specifically investigated NAC for acute uncomplicated rhinosinusitis.
In a randomized placebo-controlled trial of 20 adults with obstructive sleep apnea, NAC at 600 mg three times daily for 30 days produced significant reductions in AHI, apnea-related arousals, oxygen desaturation, daytime sleepiness, and snoring, alongside reductions in oxidative stress markers. Animal models of intermittent hypoxia also show NAC mitigates oxidative stress and reduces sympathetically-driven hypertension. An ongoing Phase 3 RCT is further evaluating NAC in OSA.
A randomized placebo-controlled trial in 20 adults with obstructive sleep apnea found that 600 mg NAC given three times daily for 30 days significantly reduced AHI, apnea-related arousals, oxygen desaturation, daytime sleepiness, and snoring (relative snore time and number of snore episodes). NAC is an antioxidant that mitigates oxidative stress and sympathetic nervous system excitation from intermittent hypoxia.
N-Acetyl Cysteine (NAC) is a precursor to glutathione and a direct antioxidant that has been studied for the prevention of noise-induced hearing loss, a major cause of tinnitus. Multiple RCTs and a systematic review support its ability to reduce oxidative cochlear damage from acoustic overexposure, thereby potentially preventing tinnitus onset.
N-Acetyl Cysteine (NAC) is approved in multiple countries as a mucolytic for respiratory conditions. It reduces mucus viscosity, has antiviral activity against influenza and RSV, and is recommended as supportive therapy for upper respiratory infections including chronic rhinosinusitis. A 2015 Cochrane review confirmed NAC reduces exacerbation rates in chronic bronchitis.
N-acetyl cysteine (NAC) is a thiol antioxidant with established anti-biofilm and antibacterial activity relevant to urinary tract infections. In vitro studies demonstrate NAC prevents E. coli and E. faecalis invasion of bladder epithelial cells, inhibits biofilm formation, and acts as a potent urease inhibitor preventing catheter encrustation in catheter-associated UTIs. Clinical studies in adults have demonstrated NAC prevents UTIs and enhances antibiotic effectiveness.
N-acetylcysteine (NAC) is a precursor to glutathione with antiviral and immune-modulatory properties against multiple viral pathogens including influenza and SARS-CoV-2. It reduces viral replication via antioxidant and interferon-signaling mechanisms. RCT and systematic review data support its role as adjunctive therapy in viral respiratory infections.
N-Acetyl Cysteine (NAC) is a glutathione precursor that plays a central role in hepatic detoxification, increasing glutathione-S-transferase activity and neutralizing reactive oxygen species. It is widely recognized in integrative medicine as a key liver detoxification support nutrient and is used in clinical settings for acetaminophen-induced liver toxicity.
N-Acetyl Cysteine (NAC) is a cysteine precursor and potent antioxidant that supports wound healing by replenishing glutathione, reducing oxidative stress at wound sites, and modulating inflammatory signaling. It has been studied in preclinical models and in clinical contexts for its wound-healing and tissue-regenerative properties.
Volver